SJX-653 – A Novel NK3 Antagonist

SJX-653 is a novel and selective small-molecule antagonist of the neurokinin-3 (NK3) receptor in clinical development as a once-daily non-hormonal therapy for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.  

SJX-653 has completed Phase 1 clinical studies designed to characterize its safety, tolerability and pharmacokinetic profile in postmenopausal women, the target population for future studies in patients suffering from moderate to severe vasomotor symptoms (VMS). In addition, SJX-653 was evaluated in a Phase 1 clinical study in men which included characterizing the effect of SJX-653 on pharmacodynamic markers known to be associated with NK3 receptor engagement. Results of this study in men were presented at ENDO 2019. SJX-653 has been well characterized in preclinical studies and exhibits excellent pharmaceutical properties. We are now preparing to initiate a Phase 2 clinical trial for the treatment of menopausal VMS.